Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
64.78
-0.55 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
24
25
26
27
28
29
30
31
Next >
2 Biotech Stocks That are Dirt Cheap Right Now
July 13, 2021
Biotech companies responded to the COVID-19 pandemic in a remarkable way, with vaccinations, treatments, diagnostics, and variant monitoring.
Via
Talk Markets
Exposures
COVID-19
Gilead's Remdesivir Fails To Show Antiviral Effects Against COVID-19 In Small WHO Study
July 13, 2021
According to a study published in the Annals of Internal Medicine, neither Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) nor hydroxychloroquine (HCQ)...
Via
Benzinga
Exposures
COVID-19
Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?
July 10, 2021
The battle for market share could come down to which drug has the lesser side effects.
Via
The Motley Fool
Understanding Gilead Sciences's Unusual Options Activity
July 08, 2021
Gilead Sciences (NASDAQ:GILD) shares experienced unusual options activity on Thursday. The stock price moved down to $67.64 following the option alert. Sentiment: BULLISH Option...
Via
Benzinga
Analyzing Gilead Sciences's Unusual Options Activity
July 02, 2021
Shares of Gilead Sciences (NASDAQ:GILD) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved up to $69.27. Sentiment: BEARISH...
Via
Benzinga
Donald Rumsfeld, Two-Time Defense Secretary, Dies At 88
June 30, 2021
Donald Rumsfeld, who served as Secretary of Defense when President George W. Bush sent U.S. military forces into Afghanistan in pursuit of al-Qaeda and into Iraq to topple the...
Via
Benzinga
Gilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal
June 29, 2021
Pardes Biosciences Inc, an early-stage biopharmaceutical company, and FS Development Corp. II (NASDAQ: FSII), a Foresite Capital sponsored SPAC, entered into a...
Via
Benzinga
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
June 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...
Via
Benzinga
Will This 2020 Biotech IPO Crush the Market This Year?
June 29, 2021
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
Gilead's Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients
June 28, 2021
Gilead Sciences Inc's (NASDAQ: GILD) unit Kite Pharma has announced top-line results from the primary analysis of ZUMA-7 of Yescarta (axicabtagene...
Via
Benzinga
Summer Friday
June 25, 2021
The stock market tried for another record after yesterday's late blowout over the infrastructure deal.
Via
Talk Markets
Why Arcus Biosciences' Big Reveal Wasn't Very Exciting
June 25, 2021
No news from Arcus Biosciences is bad news for the company and other industry heavyweights.
Via
The Motley Fool
Here's Why Arcus Biosciences Stock Is Rising Today
June 24, 2021
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.
Via
The Motley Fool
Arcus Biosciences Rockets, But Vague Update In Cancer Study Divides Analysts
June 24, 2021
Arcus Biosciences offered a vague update on its lung cancer regimens Wednesday, but RCUS stock rocketed on Thursday.
Via
Investor's Business Daily
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
June 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...
Via
Benzinga
Price to Earnings Ratio Insights for Gilead Sciences
June 23, 2021
Right now, Gilead Sciences Inc. (NASDAQ:GILD) share price is at $66.75, after a 0.45% decrease. Over the past month, the stock increased by 0.60%, but over the past...
Via
Benzinga
9 Health Care Stocks With Unusual Options Alerts In Today's Session
June 22, 2021
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away...
Via
Benzinga
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
June 18, 2021
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap...
Via
Talk Markets
Gilead's Kite Pharma Collaborates With Shoreline Biosciences For Cell Therapies For Cancer Settings
June 17, 2021
Kite Pharma, a unit of Gilead Sciences Inc (NASDAQ: GILD) and Shoreline Biosciences Inc, has entered into a strategic partnership to develop novel cell...
Via
Benzinga
Should You Buy Biotech ETFs Now?
June 16, 2021
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and...
Via
Talk Markets
Why Jounce Therapeutics Bounced Higher Today
June 15, 2021
The company gets a regulatory nod that will put $25 million in its pocket.
Via
The Motley Fool
Exposures
Product Safety
Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead
June 15, 2021
The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25...
Via
Benzinga
Exposures
Product Safety
Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains
June 14, 2021
Cocrystal Pharma Inc (NASDAQ: COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party...
Via
Benzinga
Exposures
COVID-19
95 Firms Going Ex-Dividend Next Week, Including Merck, Gilead Sciences And Public Storage
June 12, 2021
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend.
Via
Talk Markets
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
June 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,...
Via
Benzinga
'Halftime Report' Traders Share Their Thoughts On Gilead, IBM And More
June 10, 2021
On CNBC's "Fast Money Halftime Report," Josh Brown said ICICI Bank Ltd (NYSE: IBN) looks like it's going higher. The long-term trend in the name looks great and...
Via
Benzinga
5 Top ETFs With Exposure To Biogen
June 07, 2021
Here is a look at five ETFs with large exposure to Biogen shares.
Via
Talk Markets
5 Top ETFs With Exposure To Biogen
June 07, 2021
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...
Via
Benzinga
Exposures
Product Safety
Gilead's Trodelvy New Subgroup Data Shows Benefit in Second-Line Breast Cancer Patients
June 04, 2021
Gilead Sciences Inc (NASDAQ: GILD) has announced new data from the Phase 3 ASCENT study evaluating Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory...
Via
Benzinga
NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure
June 01, 2021
NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
...
24
25
26
27
28
29
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.